作者
Neil Herring, Cezary Szmigielski, Harald Becher, Niki Karavitaki, John AH Wass
发表日期
2009/1
期刊
Clinical Endocrinology
卷号
70
期号
1
页码范围
104-108
出版商
Blackwell Publishing Ltd
简介
Objective The use of high doses of the ergot‐derived dopamine agonist cabergoline (> 3 mg/day), especially with cumulative doses > 4000 mg, has been associated with an increase in cardiac valvular thickening and significant (moderate to severe) regurgitation. Whether lower doses commonly used in the treatment of prolactinomas (0·25–3 mg/week) are also associated with significant valvulopathy is controversial. The mitral valve tenting area, a subclinical index of leaflet stiffening, has also been correlated with the cumulative dose of cabergoline and severity of valvular regurgitation.
Design/patients/measurements We performed transthoracic echocardiography (TTE) on 50 prolactinoma patients (48% macroprolactinomas, 52% microprolactinomas, 30 male, 20 female, age 51·2 ± 2·2 years, mean ± SEM) who had been taking cabergoline for 6·6 ± 0·5 years (range 1–13 years) with cumulative doses of 443 ± …
学术搜索中的文章
N Herring, C Szmigielski, H Becher, N Karavitaki… - Clinical Endocrinology, 2009